In December 2022, GOSS 0.00%↑ fell from $9 to $2 after reporting Phase 2 data that met its primary endpoint but did not stack up against the competing pulmonary arterial hypertension (PAH) drug sotatercept.
The Phase 2 showed that $GOSS ultimately underperformed in “less sick” Class II PAH patients, but showed efficacy in the “sicker” Class III PAH population. The …